Update November 18 : NASDAQ 4702 up 0.67%, IBB at 295.25up 2.22%
Recent Small Cap picks:
CLDX 17.72 off 2.9% with profit taking.Very choppy trade.
FCSC 2.67 flat little action, despite Press Release on amputee treatment.
Foundation Medicine (FMI) at $25.86 up 2.67%. DNA tests for genetic profiling of potential cancer treatments.
KPTI $40.71 flat . Phase 2 with SINE (Selective Inhibitor of Nuclear Export).
Pacific Biosciences (PACB) $6.97 flat on high volume. SMRT technology for DNA sequencing.
Rayno Life Science Portfolios-Many stocks are up 2% +
ALKS, ALXN, GHDX, GILD, ILMN, REGN, SGEN. Large caps regain strength.
Biotechs stalled near new highs as S&P 500 hits new all time high at 2051.80.
—————-
Rayno Life Science Small Cap Picks-Recent Updates
On August 11 we suggested that traders and investors look at several speculative biotech stocks that could rally in Q4 2014. Small cap biotechs track two ETFs : IWM the Russell 2000 Index and the XBI, a biotech ETF weighted toward smaller caps. We reviewed these stocks again in later posts and on Friday November 14. These stocks and their initial price points were:
Celldex Therapeutics (CLDX) -$15
Celldex is up 33% today to $18.94 on results from their brain tumor immunotherapy trial. The Phase 2 ReACT study showed statistically significant survival benefit in patients with glioblastoma multiforme. The Celldex drug halted cancer progression in 9 out of 33 patients.
Fibrocell Bioscience (FCSC) -$2.75
The stock has struggled as it approaches $3 but we still think it is a good trade even a long term play with its autologous fibroblast technology for treating rare and serious skin disorders.
Karyopharm Therapeutics (KPTI)-$37.31
KPTI is volatile but holding above $40 with a broad trading range below and above. The Company is focused in nuclear transport technology with a pipeline of two lead products.The stock has 4 BUY ratings.
